Practice Update: Oncology
GIVE YOUR PATIENTS A KEY FOR FIRST-LINE TREATMENT OF METASTATIC MELANOMA
KEYTRUDA is indicated as monotherapy for the treatment of unresectable or metastatic melanoma in adults. ¹
PBS Information: Authority required (STREAMLINED) for treatment of metastatic melanoma. Refer to PBS Schedule for full authority information.
Before prescribing, please review the Product Information. Product Information is available at www.msdinfo.com.au/keytrudapi
Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road, Macquarie Park NSW 2113. ONCO-1231266-0000. First issued September 2017. MSDONC1105.
Made with FlippingBook Online document